Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
|Articles|August 17, 2009
- ONCOLOGY Vol 23 No 9
- Volume 23
- Issue 9
New Drug Application Filed for Vandetanib in Second-Line NSCLC
AstraZeneca announced the company has submitted a New Drug Application to the FDA for an investigational drug, vandetanib ( Zactima) 100 mg, for use in combination with chemotherapy for the treatment of advanced non–small-cell lung cancer in patients previously treated with one prior anticancer therapy.
Advertisement
Articles in this issue
about 17 years ago
Testicular Granulosa Cell Tumors: Rare Tumors Need to Be Studied Tooabout 17 years ago
Metabolic Therapiesabout 17 years ago
Bevacizumab Approved for Metastatic Renal Cell Carcinomaabout 17 years ago
Project Zero Delay Accelerates Drug’s Path to Clinical Trialabout 17 years ago
New Directions in the Systemic Treatment of Metastatic Thyroid Cancerabout 17 years ago
Radioiodine-Resistant Differentiated Thyroid Cancer: Hope for the Futureabout 17 years ago
Therapeutic Options Following Orchiectomy for Stage I SeminomaAdvertisement
Related to this article
Chinmay Jani, MD, highlights non-smoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
"As we combine more treatments…they have overlapping toxicities, and they may have the ability to synergize in a negative way," said Dwight H. Owen, MBBCh, MS.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
Setting Up an HDR Brachytherapy Program Amid a National Decline
3
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
4
16-Fraction PMRT With IMN Irradiation Noninferior in High-Risk Breast Cancer
5